Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation

September 2, 2013

A new article in the September 2013 issue of Thrombosis and Haemostasis strives to shed light on the optimal antithrombotic strategy in patients suffering from atrial fibrillation who undergo coronary stent implantation. This article shows that oral anticoagulation in patients with atrial fibrillation and high thromboembolic risk after stent implantation indeed lowers the risk of subsequent death, stroke and systemic thromboembolism. Yet when it comes to antithrombotic therapy, apparently guidelines are neglected.

The ideal antithrombotic strategy in patients with (AF) undergoing coronary is still subject to some debate. Nevertheless, patients at low risk of stroke in general receive dual , obviating the need for regular monitoring, while those at high risk theoretically would be better off with long-term oral anticoagulants. Triple therapy, consisting of oral anticoagulation, aspirin as well as at the initial phase, seemed the best option, but is associated with high bleeding rates. For patients with AF at low to intermediate risk of stroke, a dual antiplatelet therapy regime rather than triple therapy has also been suggested during the first months after placement of an intracoronary stent. In high-risk AF patients, oral anticoagulation is recommended to reduce the risk of stroke and . Recent guidelines have extended indications for oral anticoagulation to AF patients with one or more .

By gathering from a large cohort, Laurent Fauchier, MD, PhD, Professor of Cardiology, Trousseau University Hospital, Tours, France, and his colleagues wanted to find out whether oral anticoagulation at goes along with benefits in morbidity and mortality. They found that 23% of 417 investigated AF patients who underwent stent implantation received vitamin K antagonists when leaving the clinic. Oral anticoagulants were only used in a minority of patients in spite of their clinical benefit and dual antiplatelet therapy was the most common strategy in these patients (70%). The lack of oral anticoagulation at discharge, however, was independently associated with an increased risk of death, stroke and systemic thromboembolism, with older age, heart failure and a history of stroke. In short, oral anticoagulation lowered the risk of subsequent death or stroke in the afflicted. In turn, the authors concluded that oral anticoagulation should be systematically used in this patient population. He further noted that adherence to recent guidelines about management of oral anticoagulation is low in the afflicted. Thus the author urged that efforts be made to improve adherence to most recent guidelines in this patient subset, in particular since oral anticoagulation did not lead to a significantly higher risk of severe or major bleeding in this group of patients. He also pointed out that today new agents have become available which should facilitate decision-making as they are easier to use and at least as effective as vitamin K antagonists in reducing stroke rate and systemic embolism, but at the same time go along with lower major hemorrhage rates. These molecules may also be promising for AF patients with stent implantation.

In summary, the current paper demonstrates the necessity for a wider use of , as proposed in recent guidelines, in these patients because it was independently associated with a decreased risk of subsequent cardiovascular events. More needs to be done to improve outcomes in patients with AF undergoing coronary stenting.

Explore further: CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk

More information: Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation, Thromb Haemost 2013; 110: 560-568. nl5.sitepackage.de/link/2396_s … er.de/d0cc651ad99131

Related Stories

CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk

September 1, 2013
The CHADS2 stroke risk scores 0 or 1 assign more than one-third of patients in atrial fibrillation with stroke to low or intermediate risk not mandating oral anticoagulation, according to research presented at ESC Congress ...

GPs undertreat women with AF

September 1, 2013
General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that ...

Omission of aspirin from antiplatelet regimen: The WOEST study

August 28, 2012
Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and ...

Mass screening identifies untreated AF in 5% of 75-76 year olds

September 1, 2013
Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5-2% of the general population.1 Prevalence is estimated to ...

Female gender increases stroke risk in AF patients aged over 75 years by 20%

August 27, 2012
Female gender increases the risk of stroke in patients with atrial fibrillation (AF) aged >75 years by 20%, according to a study presented today at the ESC Congress 2012. The findings were presented by Anders Mikkelsen, from ...

Impact of AF on stroke risk eliminated with multiple risk factors

September 1, 2013
Patients with five or more risk factors have the same stroke risk as patients with atrial fibrillation, according to research presented at the ESC Congress today by Dr. Christine Benn Christiansen from Denmark. The study ...

Recommended for you

'Shapeshifter' that regulates blood clotting is visually captured for the first time

August 23, 2017
We are normally born with a highly sophisticated array of molecules that act as "sentries," constantly scanning our bodies for injuries such as cuts and bruises. One such molecular sentry, known as von Willebrand factor (VWF), ...

Dramatic new studies into inflammation in the infarcted heart could lead to changes in therapy

August 23, 2017
A medical research collaborative has demonstrated that the response of the human heart to an infarction is very different than previously thought. The study, led by cardiologist Borja Ibáñez and published as two independent ...

New molecule may hold the key to triggering the regeneration and repair of damaged heart cells

August 21, 2017
New research has discovered a potential means to trigger damaged heart cells to self-heal. The discovery could lead to groundbreaking forms of treatment for heart diseases. For the first time, researchers have identified ...

Researchers investigate the potential of spider silk protein for engineering artificial heart

August 18, 2017
Ever more people are suffering from cardiac insufficiency, despite significant advances in preventing and minimising damage to the heart. The main cause of reduced cardiac functionality lies in the irreversible loss of cardiac ...

Lasers used to detect risk of heart attack and stroke

August 18, 2017
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of ...

Cholesterol crystals are sure sign a heart attack may loom

August 17, 2017
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.